Clinical Trial Search

Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy — 1.55; -0.42 ratio

Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants

Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio to 48 ± 6 Hours After the Start of the APT Procedure — 1.53; 1.47; 1.52…

Primary: Percentage of Thrombus Obstruction — 33; 31; 23; 22 percentage of thrombus obstruction

Primary: Number of Participants With Major Bleeding Events — 1; 0; 0; 0 participants

Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio

Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants

Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants

Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation

Primary: Number of Participants Experiencing Adjudicated Clinically Relevant Bleeding Events Following Intravenous Infusion of DS-1040b or Placebo in Addition to Standard of Care…

Primary: Death From All Causes — 3; 4 Participants — p=<0.05

Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001

Primary: Reduction of RV/LV Ratio — 0.03; 0.30 Ratio

Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio

Primary: Subjects With Major Adverse Events — 24; 964 Participants

Primary: Right Ventricle/Left Ventricle (RV:LV) Ratio — 0.43 Change in RV/LV Diameter Ratio

Primary: Number of Participants With Normal Right Ventricular (RV) Function and Viability — 9; 5 Participants

Primary: Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal…

Primary: To Identify the Accuracy of Routine CTPA for the Distinction of CTEPH From Acute PE. — 70; 70 Sensitivity

Primary: Primary Endpoint: Composite Clinical Endpoint Constructed as a 5-Component Win Ratio — 52693; 10509 Number of Wins for the group

Primary: Change in Right Ventricle to Left Ventricle (RV/LV) Ratio Between Baseline and 48 Hours Post-procedure Assessed by Computed Tomography Angiography (CTA) — -0.45 ratio

Primary: Mean Duration of Hospitalization — 0.191; 1.393 Days — p=<.0001

Primary: Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement — 0; 136 percent change

Primary: Change in RV/LV Ratio on Echocardiogram (Matched Pairs as Available) — -22.6; -22.6 Percent change

Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001

Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants

Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137

Primary: Frequency of Symptomatic, Recurrent VTE Defined as the Composite of Deep Vein Thrombosis and/or Pulmonary Embolism — 4; 30 Participants

Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants

Primary: Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism — 13; 17; 50; 8 participants — p=0.0001